>Medicina Interna de México
>Year 2017, Issue 3
Tuberculosis in kidney transplantation
Med Int Mex 2017; 33 (3)
PDF: 382.72 Kb.
The World Health Organization defines emerging and re-emerging infectious diseases as “that appeared in some population for the first time or have previously existed, but quickly increase the incidence in the geographical area”. Tuberculosis (Tb) is one of the most deadly reemerging diseases. The discovery of isoniazid and other drugs initially led to the effective cure of Tb, emptying and dismantling sanatoriums control systems of Public Health in developed countries; its reemergence has been driven by immune deficiencies of people with HIV, which greatly increased the risk of latent infection with Mycobacterium tuberculosis progressing to active disease and is transmitted to others; the inappropriate use of antituberculosis therapy also complicates the problem, leading to the emergence and spread of drug-resistant and multidrug-resistant strains. Although Tb can affect all people, regardless of their social status, there are risk groups such as chronically immunosuppressed, being transplanted kidney “the forgotten group” by the need for drug therapy to prevent and treat rejection of their grafts, they live predisposed to infection with catastrophic natural evolution outside not be diagnosed and treated early, and the fact of facilitating the re-emergence and persistence of the disease as endemic in Mexico.
||tuberculosis, kidney transplantation, Mycobacterium tuberculosis.
Programa de Acción Específico (PAE) 2007-2012, Tuberculosis. Secretaría de Salud. 1ª ed. México, 2008.
El Control de las Enfermedades Transmisibles. Informe Oficial de la Asociación Estadounidense de Salud Pública. OPS-OMS. 18ª ed. EUA, 2005.
Fauci AS. Emerging and remerging infectious diseases: The perpetual challenge. Academic Medicine 2005;80:1079-1084.
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729.
Tan JC, Busque S, Scandling JD. Clinical management in kidney transplantation. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu AS, Brenner BM, editors. Brenner and Rector’s The Kidney. 9th ed. Philadelphia: Elsevier Saunders, 2012;2515-2519.
Mannon RB. Post-transplantation monitoring and outcomes. In: Greenberg A, editor. Primer on Kidney Diseases. 5th ed. Philadelphia: Elsevier Saunders, 2009; cap. 63.
Pham PT, Yabu J, Pham PCh, Wilkinson A. Renal transplantation. In: Lerma EV, Berns JS, Nissenson AR, editores. Current diagnosis y treatment, Nephrology y hypertension. 1st ed, United States of America: McGraw-Hill medical, 2009;474-477.
Munksgaard B. Mycobacterium tuberculosis. Am J Transplant 2004;4:37-41.
Manual para la Vigilancia Epidemiológica de la Tuberculosis. Dirección General de Epidemiología. Secretaría de Salud. 4ª ed. México, 1999.
American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerging Microbes and Infections 2016;doi:10.1038/emi.2016.10.
Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 2008;12:1352-1364.
Horsburgh CR, Rubins EJ. Latent tuberculosis infection in the United States. N Engl J Med 2011;364:1441-1448.
World Health Organization. Global tuberculosis control: a short update to the 2009 Report. Geneva: WHO, 2010. http://www.who.int/tb/features_arcHIVe/globalreport09_ update_8dec09/en/ (accessed 9 September 2015).
Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA Transplantation 1997;63:1278-1286.
Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996;61:211-215.
Boubaker K, Gargah T, Abderrahim E, Abdallah TB, Kheder A. Mycobacterium tuberculosis infection following kidney transplantation. BioMed Research International 2013;1:1-9.
Womer K, Rabb H. Immunosuppressive medications in kidney transplantation. In: Floege J, Jhonson RJ, Feehally J, editors. Comprehensive clinical nephrology. 4th ed. St Louis, Missouri: Saunders, 2010:1134-1141.
Belcon MC, Smith EK, Kahana LM, Shimizu AG. Tuberculosis in dialysis patients. Clin Nephrol 1982;17:14-18.
Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003;16:38-44.
World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: WHO, 2015. Available at http://www.who.int/tb/publications/ltbi_document_ page/en/ (accessed 23 October 2015).
García-Goez JF, Linares L, Benito N, Cervera C, et al. Tuberculosis in solid organ transplant recipients at a tertiary hospital in the last 20 years in Barcelona, Spain. Transplantation Proceedings 2009;41:2268-2270.
Chen CH, Lian JD, Cheng CH, Wu MJ, et al. Mycobacterium tuberculosis infection following renal transplantation in Taiwan. Transpl Infect Dis 2006;8:148-156.
El-Agroudy AE, Refaie AF, Moussa OM, Ghoneim MA. Tuberculosis in Egyptian kidney transplant recipients: study of clinical course and outcome. J Nephrol 2003;16:404-411.
Zhang XF, Lv Y, Xue WJ, Wang B, et al. Mycobacterium tuberculosis infection in solid organ transplant recipients: experience from a single center in China. Transplant Proc 2008;40:1382-1385.
Bodro M, Sabé N, Santín M, Cruzado JM, et al. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Transplant Proc 2012;44:2686-2689.
Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation 2010;90:695-704.
Melchor JL, Gracida C, Ibarra A. Increased frequency of tuberculosis in Mexican renal transplant recipients: A single-center experience. Transplant Proc 2002;34: 78.
Liu J, Yan J, Wan Q, Ye Q, Huang Y. The risk factors fortuberculosis in liver or kidney transplant recipients. BMC Infect Dis 2014;14:387.
Ersan S, Celik A, Atila K, Aykut Sifil A, et al. Tuberculosisin renal transplant recipients. Ren Fail 2011;33:753-757.
Lattes R, Radisic M, Rial M, Argento J, Casadei D. Tuberculosis in renal transplant recipients. Transpl Infect Dis 1999;1:98-104.
Naqvi R, Naqvi A, Akhtar S, Ahmed E, et al. Use of isoniazid chemoprophylaxis in renal transplant recipients. Nephrol Dial Transplant 2010;25:634-637.
Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect 2016;5:10.
Sidhu A, Verma G, Humar A, Kumar D. Outcome of latent tuberculosis infection in solid organ transplant recipientsover a 10-year period. Transplantation 2014;98:671-675.
Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002;347:103-109.
Nasr SH, Markowitz GS, Stokes MB, Said SM, et al. Acute postinfectious glomerulonephritis in the modern era: Experience with 86 adults and review of the literature. Medicine (Baltimore) 2008;87:21-32.
Nast CC. Infection-related glomerulonephritis: changing demographics and outcomes. Adv Chronic Kidney Dis 2012;19:68-75.
Rodríguez-Iturbe B, Burdmann EA, Barsoum RS. Glomerular diseases associated with infection. In: Floege J, Jhonson RJ, Feehally J, editors. Comprehensive clinical nephrology. 4th ed. St Louis, Missouri: Saunders, 2010;662-674.
Shang MS, Zhu N, Hao J, Wang L, et al. Membranous nephropathy associated with tuberculosis. Chin Med J (Engl) 2016;129:622-623.
Solak Y, Gaipov A, Anil M, Atalay H, et al. Glomerulonephritis associated with tuberculosis: a case report and literature review. Kaohsiung J Med Sci 2013;29:337-342.
Ram R, Swarnalatha G, Desai M, Rakesh Y, et al. Membranous nephropathy and granulomatous interstitial nephritis due to tuberculosis. Clin Nephrol 2011;76:487-491.
>Medicina Interna de México
>Year 2017, Issue 3